64 results
ARS
2023 FY
MYGN
Myriad Genetics, Inc.
17 Apr 24
Annual report to shareholders
4:33pm
through innovative genetic and precision medicine solutions and services. Our focus is on innovation and growth in three key areas where we have … blood test that predicts the gender of a fetus as early as six weeks of gestation with 99% accuracy. Innovative cell free DNA technology and precise
424B5
MYGN
Myriad Genetics, Inc.
13 Nov 23
Prospectus supplement for primary offering
6:02am
exist to help patient populations with pressing health care needs through innovative solutions and services. Our focus is on organic growth, deployment
424B5
MYGN
Myriad Genetics, Inc.
8 Nov 23
Prospectus supplement for primary offering
4:05pm
innovative solutions and services. Our focus is on organic growth, deployment of capital, including through opportunistic acquisitions, and the launch of new
ARS
eife13v
12 Apr 23
Annual report to shareholders
4:10pm
8-K
EX-99.1
rvxfefkyzn5yrpg8
5 May 22
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
7:05am
8-K
EX-99.1
8egpfol
11 Jan 22
Results of Operations and Financial Condition
4:16pm
8-K
EX-99.1
jkyi b1w39gfmj4
14 Dec 21
Departure of Directors or Certain Officers
4:13pm